AbbVie (NYSE: ABBV) announced the completion of its phase III clinical program and released results of four additional studies designed ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE